25gaa29 10.3205/25gaa29 urn:nbn:de:0183-25gaa297 Meeting Abstract Individuelles Pharmakotherapie-Management (IPM) identifiziert auch Leitlinien-assoziierte Risiken für die Arzneimitteltherapie- und Patientensicherheit Wolf Wolf Ursula U Dr. med.

Individuelles Pharmakotherapie-Management, Halle (Saale), Germany

ursula.wolf@uk-halle.de author German Medical Science GMS Publishing House

Düsseldorf

610 20251111 engl This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). M0632 29 Gesellschaft für Arzneimittelanwendungsforschung und Arzneimittelepidemiologie e.V. (GAA) 32. Jahrestagung der Gesellschaft für Arzneimittelanwendungsforschung und Arzneimittelepidemiologie Abstracts Jena 20251113 20251114 25gaa29 TextBackground: The Individual Pharmacotherapy Management (IPM) systematically identifies and rectifies drug-related risks, including those arising from guideline-based recommendations, to enhance patient safety , , , , , . Although clinical practice guidelines lack legal force, they are evidence-based, consensus-driven standards that shape diagnostic and therapeutic decision-making in routine care. Given the importance of drug therapy safety, it is long overdue that the issue of reconciling guideline adherence with patient-centred risk evaluation is addressed.Materials and Methods: The defining feature of the IPM, conceptualised by the author based on her internal medicine and clinical pharmacology background, is the adaptation of medication scores to patient scores (Figure 1 ). Drawing on her experience of conducting over 68,500 IPM analyses, the author has also approved the use of AI-assisted IPM with simulated models. In patient care, anonymised, AI-supported IPM requires informed patient consent. The IPM aims to review the medication list as accurately as possible in reference to the individual patient's condition. This uncovers real-world pathophysiological abnormalities and risk factors, particularly in the context of polypharmacy. The resulting personalised evaluation, aligned with guideline recommendations, supports the comprehensive detection of clinically relevant medication risks in the individual patient.Results: IPM also detected risks to drug therapy and patient safety that resulted from guideline-based recommendations. The major categories of risks identified include adverse drug reactions, which can manifest acutely, in the long term or cumulatively. Additional risks arise from over-prescription and drug-disease interactions. It is imperative that these risks are recognised, documented and communicated to the attending physician. While monitoring can reduce certain risks, contraindicated therapies must be strictly avoided in cases of drug-disease interaction. Examples of various contextual IPM-detected cases are presented .Conclusion: In terms of guideline recommendations, it is imperative to eliminate any additional risks to patients that may arise from the recommended drug therapy. Due to the specialization of medical disciplines, comprehensive pharmacological oversight, especially in cases of polypharmacy, is often lacking. Implementing established pharmacological expertise or AI-supported tools such as IPM can serve as effective preventive measures to ensure drug and patient safety in guideline-recommended therapy. Reconciling guideline adherence with patient-centered risk evaluation, IPM offers the unique structured approach to safeguard pharmacotherapy, prevent avoidable harm, and maintain clinical effectiveness. Drewas L Ghadir H Neef R Delank KS Wolf U Individual Pharmacotherapy Management (IPM) - I: a group-matched retrospective controlled clinical study on prevention of complicating delirium in the elderly trauma patients and identification of associated factors 2022 BMC Geriatr 29 Drewas L, Ghadir H, Neef R, Delank KS, Wolf U. Individual Pharmacotherapy Management (IPM) - I: a group-matched retrospective controlled clinical study on prevention of complicating delirium in the elderly trauma patients and identification of associated factors. BMC Geriatr. 2022;22(1):29. DOI: 10.3390/pharmaceutics15092300 https://doi.org/10.3390/pharmaceutics15092300 Wolf U Drewas L Ghadir H Bauer C Becherer L Individual Pharmacotherapy Management (IPM-II) for Patient and Drug Safety in Polypharmacy via Clinical Electronic Health Record Is Associated with Significant Fall Prevention 2024 Pharmaceuticals (Basel) 1587 Wolf U, Drewas L, Ghadir H, Bauer C, Becherer L, et al. Individual Pharmacotherapy Management (IPM-II) for Patient and Drug Safety in Polypharmacy via Clinical Electronic Health Record Is Associated with Significant Fall Prevention. Pharmaceuticals (Basel). 2024;17(12):1587. DOI: 10.3390/ph17121587 https://doi.org/10.3390/ph17121587 Wolf U Ghadir H Drewas L Neef R Underdiagnosed CKD in Geriatric Trauma Patients and Potent Prevention of Renal Impairment from Polypharmacy Risks through Individual Pharmacotherapy Management (IPM-III) 2023 J Clin Med 4545 Wolf U, Ghadir H, Drewas L, Neef R. Underdiagnosed CKD in Geriatric Trauma Patients and Potent Prevention of Renal Impairment from Polypharmacy Risks through Individual Pharmacotherapy Management (IPM-III). J Clin Med. 2023;12(13):4545. DOI: 10.3390/jcm12134545 https://doi.org/10.3390/jcm12134545 Wolf U Baust H Neef R Steinke T Individual Pharmacotherapy Management (IPM)-IV: Optimized Usage of Approved Antimicrobials Addressing Under-Recognized Adverse Drug Reactions and Drug-Drug Interactions in Polypharmacy 2022 Antibiotics (Basel) 1381 Wolf U, Baust H, Neef R, Steinke T. Individual Pharmacotherapy Management (IPM)-IV: Optimized Usage of Approved Antimicrobials Addressing Under-Recognized Adverse Drug Reactions and Drug-Drug Interactions in Polypharmacy. Antibiotics (Basel). 2022;11(10):1381. DOI: 10.3390/antibiotics11101381 https://doi.org/10.3390/antibiotics11101381 Wolf U A Drug Safety Concept (I) to Avoid Polypharmacy Risks in Transplantation by Individual Pharmacotherapy Management in Therapeutic Drug Monitoring of Immunosuppressants 2023 Pharmaceutics 2300 Wolf U. A Drug Safety Concept (I) to Avoid Polypharmacy Risks in Transplantation by Individual Pharmacotherapy Management in Therapeutic Drug Monitoring of Immunosuppressants. Pharmaceutics. 2023;15(9):2300. DOI: 10.3390/pharmaceutics15092300 https://doi.org/10.3390/pharmaceutics15092300 Wolf U A Drug Safety Briefing (II) in Transplantation from Real-World Individual Pharmacotherapy Management to Prevent Patient and Graft from Polypharmacy Risks at the Very Earliest Stage 2024 Pharmaceuticals (Basel) 294 Wolf U. A Drug Safety Briefing (II) in Transplantation from Real-World Individual Pharmacotherapy Management to Prevent Patient and Graft from Polypharmacy Risks at the Very Earliest Stage. Pharmaceuticals (Basel). 2024;17(3):294. DOI: 10.3390/ph17030294 https://doi.org/10.3390/ph17030294 Wolf U Wegener M Proton Pump Inhibitor Prescription in Nursing Home Residents: Prevalence, Appropriateness, and Associated Factors-A Secondary Data Analysis from Three German Regions and the Impact of Guideline Recommendations 2024 Pharmaceuticals (Basel) 1082 Wolf U, Wegener M. Proton Pump Inhibitor Prescription in Nursing Home Residents: Prevalence, Appropriateness, and Associated Factors-A Secondary Data Analysis from Three German Regions and the Impact of Guideline Recommendations. Pharmaceuticals (Basel). 2024 Aug 17;17(8):1082. DOI: 10.3390/ph17081082 https://doi.org/10.3390/ph17081082 0

1 1 Figure 1: Comprehensive, reproducible Individual Pharmacotherapy Management to identify and counteract individual pathophysiological patient conditions which may be iatrogenically induced by drugs. * IPM (applied Patient and Medication Scores) based on the inpatient Electronic Health Record (EHR) and Summaries of Product Characteristics (SmPCs), defined, conceptualised, implemented and practised by Ursula Wolf, MD, Head of Pharmacotherapy Management Department, Specialist in Internal Medicine with expertise in Clinical Pharmacology, performed >65,800 individual medication reviews for polypharmacy in elderly trauma, dementia, transplant and intensive care patients. The IPM physician applies the SmPCs by matching their evidence-based defined risks to the digitally captured individual Patient Scores which provide the necessary ‘comprehensive patient overview’.

1 0 0